



Divi's Laboratories Limited

Date.8th November 2013

The Manager
Listing Department
National Stock Exchange of India Limited
Exchange Plaza
Bandra-Kurla Complex, Bandra (East)
MUMBAI – 400 051

(by Fax, email & Courier)

Fax Nos.022 – 2659 8237 / 38

Dear Sir,

**Sub: Un-audited financial results for the first quarter ended
30th September 2013 and limited review report –reg**
Ref: Clause 41 of Listing Agreement - Stock code: DIVISLAB
###


Pursuant to Clause 41 of the Listing Agreement, please find enclosed un-audited financial results along with the limited review report for the first quarter ended **30th September 2013.**

Above un-audited financials were approved and taken on record by the Board of Directors of the Company at their meeting held on **Friday, 8th November 2013.**

The Company proposes release of press note as per the enclosed format. This is for your information and records. Kindly acknowledge the receipt of the same.

Thanking You,

Yours faithfully,
For Divi's Laboratories Limited


L Kishorebabu
Chief Financial Officer
Encl: a/a

“An ISO-9001, ISO-14001 and OHSAS-18001 Triple certified company”

Regd. Off : Divi Towers, 7-1-77/E/1/303, Dharam Karan Road, Ameerpet, Hyderabad - 500 016. INDIA

Tel : 91-40-2378 6300, Fax : 91-40-2378 6460


E-mail : mail@divislaboratories.com, Website : www.divislaboratories.com

DIVI'S LABORATORIES LIMITED

UNAUDITED FINANCIAL RESULTS (STANDALONE) FOR THE QUARTER AND HALF YEAR ENDED 30TH SEPTEMBER, 2013

(₹. in Lakhs)

Sl No.	Particulars	STANDALONE					
		Unaudited					Audited
		Quarter ended			Half Year ended		Year Ended
		30.09.2013	30.06.2013	30.09.2012	30.09.2013	30.09.2012	31.03.2013
	(1)	(2)	(3)	(4)	(5)	(6)	(7)
1	Income from operations						
	(a) Net Sales/Income from operations (Net of Excise Duty)	56588	51588	47260	108176	94101	212395
	(b) Other Operating Income	107	127	114	234	224	494
	Total Income from operations (net)	56695	51715	47374	108410	94325	212889
2	Expenses						
	a. Cost of materials consumed	28149	28389	23131	56538	40388	89790
	b. Purchases of stock-in-trade		0	0		0	9
	c. Changes in inventories of finished goods, work-in-progress and stock-in-trade	(10133)	(10640)	(6978)	(20773)	(8152)	(10033)
	d. Employee benefits expense	5615	5303	4337	10918	9182	19120
	e. Depreciation and amortization expense	2252	2088	1879	4340	3627	7690
	f. Other Expenses	8192	8945	10385	17137	15176	31828
	Total Expenses	34075	34085	32754	68160	60221	138404
3	Profit from Operations before Other Income, Interest & Exceptional Items (1-2)	22620	17630	14620	40250	34104	74485
4	Other Income	3654	5342	847	8996	2835	4851
5	Profit from ordinary activities before finance costs & exceptional Items (3+4)	26274	22972	15467	49246	36939	79336
6	Finance Costs	39	41	31	80	72	178
7	Profit from ordinary activities after finance costs but before exceptional Items (5-6)	26235	22931	15436	49166	36867	79158
8	Exceptional items	0	0	0	0	0	0
9	Profit from ordinary activities before Tax (7-8)	26235	22931	15436	49166	36867	79158
10	Tax Expense	5742	5460	3639	11202	8332	18016
11	Net Profit from ordinary activities after Tax (9-10)	20493	17471	11797	37964	28535	61142
12	Extra-ordinary items (net of tax expense)	0	0	0	0	0	0




1. The above results for the quarter ended 30th September 2013, as reviewed by the Audit Committee, were considered and approved by the Board of Directors at its meeting held on 8th November, 2013 and were subjected to 'limited review' by the Auditors.
2. The Company is primarily engaged in the manufacture of Active Pharmaceutical Ingredients and intermediates. Accordingly there are no reportable segments as per Accounting Standard 17 notified under the Companies Act, 1956.
3. As per Clause 41 of the listing agreement, the company has opted to publish quarterly unaudited standalone results and to publish consolidated results at the year end.
4. Details of forex gain/loss are given below:

	Quarter ended			Half Year ended		Year Ended
	30.09.2013	30.06.2013	30.09.2012	30.09.2013	30.09.2012	31.03.2013
Forex gain/(loss)	3123	4253	(2078)	7376	926	1516

Forex gain has been included in Other Income and forex loss has been included in Other Expenses.

5. Figures for the previous year/period have been regrouped or recasted, wherever necessary.

for Divi's Laboratories Limited


Dr. Murali K. Divi
Chairman & Managing Director



Place: Hyderabad
Date: 8th November, 2013

DIVI'S LABORATORIES LIMITED

Hyderabad

PRESS RELEASE dated 8th November, 2013


Divi's Labs earns a PAT of Rs.205 crores in Q2 of FY14

Divi's Laboratories has earned a Profit after Tax (PAT) of Rs.205 crores on a total income of Rs.567 crores, on a stand-alone basis, for the quarter ended 30th September, 2013. For the corresponding quarter of the last year, the company earned a PAT of Rs.118 crores on a total income of Rs. 474 crores.

Forex gain for the current quarter amounted to Rs.31 crores as against a loss of Rs.21 crores during the corresponding quarter of last year.

For the half year ended 30th September, 2013, the company earned a total income of Rs.1084 crores as compared to an income of Rs. 943 crores during the previous half-year. PAT for the current half-year came to Rs. 380 crores as against Rs. 285 crores for the previous half-year.

The company has capitalized fixed assets aggregating to Rs.120 crores during the current half-year.





P.V.R.K. Nageswara Rao & Co.,
Chartered Accountants

LIMITED REVIEW REPORT

TO
THE BOARD OF DIRECTORS OF
DIVI'S LABORATORIES LIMITED

We have reviewed the accompanying statement of unaudited financial results of **DIVI'S LABORATORIES LIMITED** for the period ended **30th September, 2013** except for the disclosures regarding 'Public Shareholding' and 'Promoter and Promoter Group Shareholding' which have been traced from disclosures made by the management and have not been audited by us. This statement is the responsibility of the Company's Management and has been approved by the Board of Directors / Committee of Board of Directors. Our responsibility is to issue a report on these financial statements based on our review.

We conducted our review in accordance with the Standard on Review Engagements (SRE) 2410, "Review of Interim Financial Information Performed by the Independent Auditor of the Entity" issued by the Institute of Chartered Accountants of India. This standard requires that we plan and perform the review to obtain moderate assurance as to whether the financial statements are free of material misstatement. A review is limited primarily to inquiries of company personnel and analytical procedures applied to financial data and thus provide less assurance than an audit. We have not performed an audit and accordingly, we do not express an audit opinion.

Based on our review conducted as above, nothing has come to our attention that causes us to believe that the accompanying statement of unaudited financial results prepared in accordance with the applicable accounting standards notified pursuant to the companies (Accounting Standard) Rules, 2006 as per section 211(3C) of the Companies Act, 1956 and other recognised accounting practices and policies has not disclosed the information required to be disclosed in terms of Clause 41 of the Listing Agreement including the manner in which it is to be disclosed, or that it contains any material misstatement.


For P.V.R.K. NAGESWARA RAO & Co.,
Chartered Accountants
Firm's Registration Number: 002283S

N. Anka Rao

N. ANKA RAO

Partner

Membership Number: 23939



HYDERABAD
08.11.2013